drugset / Trial / NCT01281696
Bevacizumab With Etoposide and Cisplatin in Breast Cancer Patients With Brain and/or Leptomeningeal Metastasis
Phase 2
Completed
40 enrolled
National Taiwan University Hospital
Chang Gung Memorial Hospital · collabTaichung Veterans General Hospital · collabTaipei Veterans General Hospital, Taiwan · collab
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to investigate the efficacy of bevacizumab, etoposide and cisplatin in treating breast cancer patients with central nervous system metastasis (including brain parenchymal and leptomeningeal metastasis).
Timeline
- Start
- 2011-01
- Primary completion
- 2013-07
- Completion
- 2013-10
Publications
- Chen BB, Lu YS, Lin CH, Chen WW, Wu PF, Hsu CY, Yu CW, Wei SY, Cheng AL, Shih TT. A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer. BMC Cancer. 2016 Jul 13;16:466. doi: 10.1186/s12885-016-2494-8.
- Wu PF, Lin CH, Kuo CH, Chen WW, Yeh DC, Liao HW, Huang SM, Cheng AL, Lu YS. A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis. BMC Cancer. 2015 Apr 17;15:299. doi: 10.1186/s12885-015-1290-1.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | — |
| Subject | Cisplatin | Other / unclassified | 70 mg/m2 | — |
| Subject | Etoposide | Small molecule | 70 mg/m2 | — |
| Background | Methotrexate | Small molecule | — | Intrathecal |